Yaping Long
Overview
Explore the profile of Yaping Long including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Long Y, Ge X, Zhang P, Li T, Wu L, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772073
Combining radiotherapy with targeted therapy benefits patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer (EGFRm NSCLC). However, the optimal strategy to combine EGFR tyrosine kinase inhibitors (TKIs)...
2.
Long Y, Xu Z, Yu J, Hu X, Xie Y, Duan X, et al.
Anticancer Drugs
. 2024 Jul;
35(9):830-843.
PMID: 39016262
There is a substantial unmet need for effective treatment strategies in triple-negative breast cancer (TNBC). Recently, renewed attention has been directed towards targeting glutamine (Gln) metabolism to enhance the efficacy...
3.
Qin B, Xin L, Liang C, Li L, Song Q, Long Y, et al.
BMC Cancer
. 2024 Jan;
24(1):100.
PMID: 38233798
Background: Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment...
4.
Long Y, Yang W, Bai Y, Tao H, Zhang F, Wang L, et al.
Cancer Cell Int
. 2023 Sep;
23(1):224.
PMID: 37777758
Background: Hyper progressive disease (HPD) describes the phenomenon that patients can't benefit from immunotherapy but cause rapid tumor progression. HPD is a particular phenomenon in immunotherapy but lacks prediction methods....
5.
Yang W, Li T, Bai Y, Long Y, Gao M, Wang T, et al.
Front Oncol
. 2023 May;
13:1147903.
PMID: 37124534
Importance: Both pembrolizumab and sintilimab have been approved by the Chinese State Drug Administration (NMPA) for the first-line treatment of patients with advanced squamous lung cancer. The differences of the...
6.
Han X, Long Y, Duan X, Liu Z, Hu X, Zhou J, et al.
Exp Cell Res
. 2022 Jan;
412(2):113044.
PMID: 35093305
Purpose: Transcription factor zinc finger E-box binding homeobox 1(ZEB1) was well-known as a transcription factor in epithelial-mesenchymal transition (EMT) process of cancer, but little is known about its role in...
7.
Long Y, Xiong Q, Song Q, Li Y, Li X, Qin B, et al.
Thorac Cancer
. 2021 Dec;
13(3):394-403.
PMID: 34958168
Background: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. Resistance to osimertinib remains a clinical challenge. However, the...
8.
Han X, Duan X, Liu Z, Long Y, Liu C, Zhou J, et al.
Breast Cancer Res Treat
. 2021 Jun;
188(2):329-342.
PMID: 34169392
Purpose: Prior studies have noted that zinc finger E-box binding homeobox 1 (ZEB1) is a master transcription regulator, affecting the expression of nearly 2000 genes in breast cancer cells, especially...
9.
Long Y, Gao Z, Hu X, Xiang F, Wu Z, Zhang J, et al.
Cancer Med
. 2018 Jul;
7(9):4690-4700.
PMID: 30051648
Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies. We performed an experiment using BALB/C mice, and our results showed that ShMCT4 transfection...
10.
Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F, et al.
Cancer Med
. 2018 May;
7(8):4115-4120.
PMID: 29797416
Immune checkpoint blockade-related pneumonitis is a rare but potentially life-threatening adverse effect, but its risk factors are not completely understood. This case-control study was conducted to identify pneumonitis risk factors...